ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2019年01月23日 09時00分
Source:
Eisai
エーザイ、「世界で最も持続可能な100社」に4回目の選定
日本企業で最上位にランク
東京, 2019年01月23日 - (JCN Newswire) - エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫)は、このたび、カナダの出版社コーポレートナイツ社が選定する「2019年 世界で最も持続可能な100社」(2019 Global 100 Most Sustainable Corporations in the World、以下「Global 100」)に選出されましたのでお知らせします。当社は、今回が4回目の選出となります。日本企業からは当社を含む8社が選出され、当社は日本企業で最上位の73位にランクされました。
「Global 100」は、世界の主要企業約7,500社を対象に、ESG(環境、社会、ガバナンス)等に関する取り組みから持続可能性を評価し、世界の上位100社を選出するもので、2005年から世界経済フォーラム(ダボス会議)に合わせて毎年発表されています。具体的な評価指標としては、財務状況、健全な収益、サプライヤー評価、従業員マネジメントや資源有効活用といった21項目が設定され、各企業の財務情報や統合報告書などの開示情報に基づいて評価されます。
当社は、患者様とそのご家族の喜怒哀楽を第一義に考え、そのベネフィット向上に貢献し、世界のヘルスケアの多様なニーズを充足することを企業理念と定めています。当社は、このヒューマン・ヘルスケア(hhc)理念のもと、ESGへの取り組みを強化し、非財務価値を高めることにより、持続的企業価値向上に努めてまいります。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2019/news201906.html
概要:エーザイ株式会社
詳細はwww.eisai.co.jpをご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Island States Ocean Summit Concludes Launch of the "OCEAN STATES INITIATIVE"
Jun 08, 2026 14:00 JST
ONERHT Foundation Raises Over S$280,000 for Local Charities and Announces New Leadership at 11th Anniversary Charity Golf & Gala Dinner
Jun 05, 2026 11:00 JST
Operations Started for the Nagaoka Methanation Demonstration Utilizing the CO2NNEX(R) Digital Platform for Transfer and Management of e-Methane Clean Gas Certificates
Jun 04, 2026 23:49 JST
Fujitsu and Daiichi Life Group Launch Joint Research to Advance Asset Management with Quantum Technology
Jun 04, 2026 23:17 JST
"Making Children and Adults Smile:" Honda Launches the SMILE RIDER PROJECT
Jun 04, 2026 22:46 JST
GR Premiers GRMN Corolla
Jun 04, 2026 22:05 JST
Island States Ocean Summit Opens in Tokyo
Jun 04, 2026 12:00 JST
Mazda and Nippon Express Launch Demonstration Trial Using Biodiesel Fuel
Jun 04, 2026 00:26 JST
NEC Wins at the Newsweek AI Impact Awards 2026
Jun 04, 2026 00:09 JST
Mitsubishi Heavy Industries and Preferred Networks Form Business Alliance to Jointly Develop Japan-Made AI Technologies for Mission-Critical Applications
Jun 03, 2026 23:51 JST
JAL Engineering and Mitsubishi Heavy Industries Establish Joint Venture "Aero Breath" for Aircraft Aftermarket Business
Jun 03, 2026 23:27 JST
MHI Receives Waste Treatment Technology Verification Report from JESC for Its Biomass High-Efficiency Recovery and Recycling System AdBio
Jun 03, 2026 23:02 JST
DUNLOP and Fujitsu Reduce Tire Structural Analysis Time by Approximately 90% Using AI
Jun 03, 2026 22:31 JST
153 elevators and escalators delivered for the New Taipei Metro Sanying Line in Taiwan
Jun 03, 2026 11:00 JST
Fujitsu Launches AI-Powered Service to Analyze Non-Financial Disclosure and Enhance Corporate Value
May 29, 2026 22:11 JST
Sigenergy Unveils SigenAgent, the First All-Domain AI Agent for the Renewable Energy Industry
May 29, 2026 21:47 JST
Wheelchair Racer Catherine Debrunner Breaks Her Own World Record, Sets New Mark in the 200 Meters (T53) at the World Para Athletics Grand Prix (Switzerland)
May 27, 2026 22:45 JST
Fujitsu signs strategic partnership with Anthropic
May 27, 2026 22:03 JST
Fujitsu to accelerate AI transformation in Japan's enterprise sector through collaboration with OpenAI
May 27, 2026 21:18 JST
Hitachi Energy and Volvo Construction Equipment announce collaboration to accelerate zero-emission construction sites
May 27, 2026 20:19 JST
More Latest Release >>
Related Release
Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
5/22/2026 12:23:00 AM JST
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
4/21/2026 8:52:00 PM JST
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
3/27/2026 8:14:00 PM JST
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
3/27/2026 6:19:00 PM JST
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
3/23/2026 11:19:00 AM JST
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
3/19/2026 10:54:00 AM JST
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
3/17/2026 7:49:00 PM JST
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
3/12/2026 5:21:00 PM JST
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
3/11/2026 12:07:00 PM JST
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
3/2/2026 9:49:00 AM JST
More Press release >>